Altimmune公布Pemvidutide治疗酒精使用障碍Reclaim二期试验数据,入选2026年AASLD肝脏会议®最新突破口头报告

美股速递
Nov 05

Altimmune公司宣布,其Pemvidutide用于治疗酒精使用障碍的Reclaim二期临床试验数据,已获选为2026年AASLD肝脏会议®的最新突破口头报告。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10